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Abstract
Background: Patients with high Gleason score, elevated prostate specific antigen (PSA) level, and advanced clinical
stage are at increased risk for both local and systemic relapse. Recent data suggests higher radiation doses
decrease local recurrence and may ultimately benefit biochemical, metastasis-free and disease-specific survival. No
randomized data is available on the benefits of long-term hormonal therapy (HT) in these patients. A prospective
study on the efficacy and safety of trimodality treatment consisting of HT, external beam radiation therapy (EBRT),
and brachytherapy (BT) for high-risk prostate cancer (PCa) is strongly required.
Methods/Design: This is a phase III, multicenter, randomized controlled trial (RCT) of trimodality with BT, EBRT, and
HT for high-risk PCa (TRIP) that will investigate the impact of adjuvant HT following BT using iodine-125 (
125I-BT)
and supplemental EBRT with neoadjuvant and concurrent HT. Prior to the end of September 2012, a total of 340
patients with high-risk PCa will be enrolled and randomized to one of two treatment arms. These patients will be
recruited from more than 41 institutions, all of which have broad experience with
125I-BT. Pathological slides will be
centrally reviewed to confirm patient eligibility. The patients will commonly undergo 6-month HT with combined
androgen blockade (CAB) before and during
125I-BT and supplemental EBRT. Those randomly assigned to the long-
term HT group will subsequently undergo 2 years of adjuvant HT with luteinizing hormone-releasing hormone
agonist. All participants will be assessed at baseline and every 3 months for the first 30 months, then every 6
months until 84 months from the beginning of CAB.
The primary endpoint is biochemical progression-free survival. Secondary endpoints are overall survival, clinical
progression-free survival, disease-specific survival, salvage therapy non-adaptive interval, and adverse events.
Discussion: To our knowledge, there have been no prospective studies documenting the efficacy and safety of
trimodality therapy for high-risk PCa. The present RCT is expected to provide additional insight regarding the
potency and limitations of the addition of 2 years of adjuvant HT to this trimodality approach, and to establish an
appropriate treatment strategy for high-risk PCa.
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Background
The majority of low-risk patients with clinically localized
prostate cancer (PCa) have a high likelihood of disease-
free survival regardless of the treatment option chosen
[1]. In contrast, patients with high-risk PCa with high
Gleason score, elevated prostate specific antigen (PSA)
level, and advanced clinical stage are at greater risk for
treatment failure after initial management by single
treatment modalities, such as radical prostatectomy
(RP), external beam radiation therapy (EBRT), or bra-
chytherapy (BT) [2,3]. Therefore, it is extremely impor-
tant to establish the most effective and safe treatment
strategy for patients with high-risk PCa, preventing local
recurrence and biochemical failure at an early stage dur-
ing treatment. However, high-risk PCa remains a thera-
peutic challenge for both urologists and radiation
oncologists.
As high-risk patients have locally advanced disease
with the possibility of direct extension and/or local
micrometastases, various combinations of each mono-
therapy described above have been developed to aug-
ment disease-free survival. Recently, several studies
concerning radiation therapy (RT)-based trimodality
treatment method with BT, EBRT, and hormonal ther-
apy (HT) were reported [4-6]. According to the Ameri-
can Brachytherapy Society (ABS), BT alone is not
recommended for high-risk PCa but can be used as a
boost in conjunction with EBRT [7]. Thus, the combina-
tion of BT and EBRT in this multimodal treatment
approach theoretically delivers an escalated dose to the
prostate, including extraprostatic extension (EPE)
increasing the probability of eradicating all of the local
disease. With respect to HT, neoadjuvant and concur-
rent androgen deprivation also offers both cytoreduction
and synergistic enhancement of RT in high-risk PCa;
adjuvant HT may play a role in elimination of occult
systemic disease and have multiple synergistic effects to
radiation on local control due to induction of apoptosis
[8,9].
Some previous studies demonstrated a benefit of HT
used in conjunction with EBRT to treat locally advanced
prostate cancer [10-12]. However, these studies, which
demonstrated an advantage with the addition of HT,
were done when the radiation dose may have been
inadequate to control all local disease. The question
therefore that has never been answered is what benefit,
if any will long-term androgen deprivation have when
much higher radiation doses are delivered. Although the
ABS recommends HT in conjunction with BT for
cytoreduction of prostate volume, there are no clear
indications for using adjuvant HT in intermediate- to
high-risk PCa [7]. Moreover, both neoadjuvant and
adjuvant HT may significantly induce adverse events,
including fatigue, diminished sexual function, and hot
flushes and possible early death [13,14]. Accordingly,
investigation of the best optimal duration of HT with
maximization of outcome while minimizing toxicity is a
logical step in the management of localized high-risk
PCa, because the prolonged use of HT may result in an
increase in adverse events. It is necessary to determine
which patients with high-risk PCa will actually benefit
from HT despite some compromises in quality of life
(QOL) associated with the adverse event profile of this
treatment.
As mentioned above, the optimal RT-based trimodal-
ity protocol for use in high-risk PCa remains controver-
sial. However, there have been no prospective studies
regarding the efficacy and safety of trimodality treatment
with combined HT, EBRT, and BT for high-risk
patients. Such prospective clinical trials are necessary.
H e r e ,w ed e s c r i b eo u rs t u d yp r o t o c o lf o rh i g h - r i s kP C a ,
which is a phase III, multicenter, randomized controlled
trial (RCT) of a trimodality treatment protocol with BT
using iodine-125 (
125I-BT), EBRT, and neo-adjuvant and
concurrent HT for 6 months with or without adjuvant
HT for 2 years. We also assessed whether short-term
H Tw i t h o u ta d j u v a n tH To rl ong-term HT with adju-
vant HT is better with regard to improved local control
and biochemical cure rate in high-risk localized PCa.
The final goal of this study is to establish an appropriate
treatment strategy for high-risk PCa without increasing
the occurrence of adverse events.
Methods/Design
Aim of the study
To evaluate the efficacy and safety of long-term vs.
short-term HT in the setting of trimodality therapy with
125I-BT, EBRT, and HT in high-risk PCa patients.
Study design
The present study is a phase III, multicenter, RCT of a
trimodality treatment protocol with
125I-BT plus supple-
mental EBRT with short- or long-term HT for patients
with untreated high-risk PCa. We will randomly assign
patients with high-risk PCa who have received
125I-BT
and supplemental EBRT plus 6 months of HT with
combined androgen blockade (CAB) into two groups:
one receiving no further treatment and another
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releasing hormone agonist (LH-RHa) (Figure 1).
Additional measures
Two validated QOL questionnaires, the SF-8™,w h i c h
has been translated into Japanese, and the Expanded
Prostate Cancer Index Composite (EPIC), will be admi-
nistered prior to hormonal therapy and at the 60
months after the beginning of CAB to comprehensively
cover the various aspects of physical and psychosocial
wellbeing.
Site selection
For an institution to participate, the institution’s attend-
ing physicians must:
a. Acquire certified documentation of participation in
the Japanese Brachytherapy Scientific Meeting’st r a i n i n g
session for the
125I-BT procedures.
6M HT with CAB (3M before and 3M during RT)
125I-   BT plus supplemental EBRT
Central Review of Pathological Diagnosis
Randomization
2Y HT with LH-RHa
Eligibility Criteria
Patients must:
1. Be 40 to 79 years age, with a definitive histological diagnosis of PCa by needle biopsy.
2. Have high risk PCa where at least one of the following three factors is satisfied:
1) initial PSA>20 ng/mL, 2) Clinical stage of T2c or T3a, 3) Gleason score 8-10.
3. Be previously untreated for prostate cancer.
4. Demonstrate appropriate bone marrow, hepatic and renal function in laboratory tests
within two weeks prior to registration.
a) WBC  3,000 /μL
b) Hemoglobin level  10.0 g/dL
c) Platelet count  10.0 x 104/μL
d) Serum creatine level  2.0 mg/dL
e) ALT and AST levels  100 IU/L
5. Agree in writing to participate in this clinical study after receiving adequate explanation.
Long-term HT Group  Short-term HT Group 
No further treatment
(n=170) (n=170)
Figure 1 Study design of TRIP (UMIN000003992).
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125I-BT in at least 50 patients.
c. Regularly perform
125I-BT procedures.
Eligibility criteria - Inclusion criteria
Patients must:
a. Be from 40 to 79 years of age when obtaining writ-
ten informed consent.
b. Have high-risk PCa with a definitive histological
diagnosis by needle biopsy. In this study, high risk is
defined as those cases in which where at least one of
the following three conditions is satisfied: 1) PSA > 20
ng/mL prior to CAB, or 2) clinical stage of T2c or T3a,
or 3) Gleason score ≥ 8 as determined by central patho-
logical judgment.
c. Performance status of 0-1, according to the Eastern
Cooperative Oncology Group.
d. Previously untreated for PCa.
e. Appropriate bone marrow, hepatic, and renal func-
tion as demonstrated in laboratory tests within two
weeks prior to registration.
a) WBC ≥ 3000/μL.
b) Hemoglobin level ≥ 10.0 g/dL.
c) Platelet count ≥ 10.0 × 10
4/μL.
d) Serum creatine level ≤ 2.0 mg/dL.
e) ALT and AST levels ≤ 100 IU/L.
f. Computed tomography (CT) and bone scan without
evidence of metastases
Eligibility criteria - Exclusion criteria
Patients are ineligible if they:
a. Have previously received surgery and/or hyperther-
mia for BPH.
b. Exhibit clinical stage ≥ T3b.
c. Have a second cancer that requires treatment.
d. Have collagen diseases.
e. Have poorly controlled ischemic cardiac disease.
f. Have poorly controlled hypertension (i.e., diastolic
pressure ≥ 120 mmHg)
g. Have a severe psychiatric disorder, including schizo-
phrenia and dementia.
h. Have poorly controlled diabetes.
i. Are using steroid drugs other than topical
ointments.
j. Are using antiandrogenic therapy.
k. Are considered by a principal or clinical investigator
to be inappropriate for participation in the present study
for any other reason.
Informed consent - ethics approval
The study was conducted in accordance with the
Declaration of Helsinki 1975, as revised in 2000. All
treatments for prostate cancer are undertaken following
written informed consent, and further consent is
obtained for procedures to confirm the high-risk diag-
nosis. This study received approval from the Foundation
for Biomedical Research and Innovation, Translational
Research Informatics Center (TRI) ethical review com-
mittee (approval No. 10-12, date Sep 10th, 2010) and
the institutional ethics committees of the participating
institutions.
Methods of recruitment and random allocation
Recruitment of patients is supported by the tri-modality
therapy with
125I-BT and EBRT and short- or long-term
HT for High-risk Localized PCa (TRIP) Study Group.
Recruiting began in October 2010, and is planned for
completion by September 2012. All prostatic biopsy his-
tological slides of newly diagnosed prostate cancer since
the initiation of the study have been reviewed by central
pathologists, with patient eligibility determined at the
time of review. Eligible patients are randomly assigned
to one of two treatment arms through the data center at
the TRI. Randomization is done centrally using a mini-
mization method to obtain good between-group balance
for factors including age category (< 70/≥ 70), PSA cate-
gory (≤ 20/> 20 ng/mL), Gleason score by central patho-
logical judgment category (< 8/≥ 8), and institutions.
Technique of
125I-BT
125I-BT for all patients is administered using an ultra-
sound-guided technique with the Mick applicator [15].
The implant is planned to deliver a prescription dose of
110 Gy or more to the clinical target volume (CTV),
which includes the prostate gland and treatment margin
[16]. Although individual technical aspects are institu-
tion-dependent, efforts are made to ensure optimal qual-
ity control of the radiation dose. Standardization
included training in real-time computer assisted intrao-
perative technique [17], three types of I-125 activity
levels based on prostate volume (< 15 cc; 0.25-0.29 mCi,
15-40 cc; 0.3-0.34 mCi and > 40 cc; 0.35-0.4 mCi), pros-
tate D90 (the mean dose received by 90% of target
volume) > 110 Gy, V100 (the mean volume receiving
100% of the prescription dose) > 95%, V150 (the mean
volume receiving 150% of the prescription dose) < 60%,
urethral V150 (mL) = 0 mL and maximum urethral
dose < 220 Gy, rectal V100 (mL) < 0.1 mL. CT images,
taken at 2-5 mm intervals, are obtained within 3-7
weeks after
125I-BT to determine dose-volume histogram
(DVH) for the prostate, urethra, and rectum [16,18]. We
organized a quality control committee for this study to
assess the variance of postimplant dosimetry. This board
will meet regularly while this protocol is running to
monitor and compare dosimetry. Although the prescrip-
tion dose for the I-125 is 110 Gy, the board recognizes
that post-implant D90 may vary. One of the goals of the
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dose of delivered dose. Therefore, as long as the rectal
V100 < 1.0 mL and the urethral D10 (the mean dose
received by 10% of target volume) < 200 Gy each center
will be allowed to adjust the EBRT total dose if the I-
125 D90 < 100 or > 140 Gy. The results of comparative
analysis will be reported separately.
Supplemental EBRT
From 4 to 8 weeks after
125I - B T ,4 5G yo fE B R Ti n2 5
fractions is routinely delivered by three-dimensional
conformal radiation therapy (3D-CRT) using ≥ 6M V
photons or intensity-modulated radiation therapy
(IMRT). Generally, a daily fraction of 1.8 Gy will be
administered 5 days per week for 5 weeks. If the D90
form the implant is < 100 Gy up to the total dose of
50.4 Gy (1.8 Gy × 28) and if the dose is > 140 Gy the
EBRT will be reduced to 39.6 Gy (1.8 Gy × 22).
3D-CRT will be delivered with 4 or more fields iso-
centric beam setup based on CT. The technical aspects
of IMRT delivery are institution-dependent.
The clinical target volume (CTV) is defined as the
prostate and the proximal seminal vesicle (SV) within 1
cm from the prostate-SV junction [19]. No attempt is
made to treat the pelvic lymph nodes. A planning target
volume (PTV) is applied to the CTV such that there is a
block margin of 1.5-2 cm around the CTV. Position ver-
ification and correction are performed by standard port
film imaging in the case of 3D-CRT and with orthogo-
nal film isocenter verification in the case of IMRT.
Contents of HTx
HT with CAB consists of a subcutaneous LH-RHa
administration in conjunction with oral antiandrogen
for 3 months before and continuing for 3 months after
125I - B T .A f t e r6m o n t h so fH T ,t h ep a t i e n t sw e r e
assigned to receive no further HT treatment or to con-
tinue HT with the same LH-RHa but without the anti-
androgen for an additional 2 years. Bicalutamide (80
mg/day) is used as an oral antiandrogen, and either
goserelin acetate (3.6 mg per month or 10.8 mg every 3
months) or leuprolide acetate (3.75 mg per month or
11.25 mg every 3 months) is subcutaneously injected as
LH-RHa.
Data collection
This study design was chosen to ensure accurate, stan-
dardized, and high-quality data collection. All patients
giving written informed consent to the study are asked
to complete a short family history and epidemiology
questionnaire. Electronic Data Capture (EDC) systems
are used to collect clinical data in electronic format,
with clinical data being obtained from patient medical
records by the Translational Research Informatics
Center. A follow-up data form is completed by the Clin-
ical Trials Practitioner (CTP) at diagnosis, 3, 6, 9, 12,
15, 18, 21, 24, 27, and 30 months, and then every 6
months until 84 months from the date of commence-
ment of CAB. These forms capture information regard-
ing patient characteristics, disease presentation,
diagnosis and treatment, PSA, recurrence and survival.
Annual follow-up is continued until death, loss to fol-
low-up, or the end of the active phase of the study (Sep-
tember 2022).
Definition of endpoints
The primary endpoint is biochemical progression-free
survival (bPFS). Biochemical progression is defined as an
increase in PSA of ≥ 2 ng/mL from the nadir value fol-
lowing treatment. Secondary endpoints are: 1) OS, 2)
clinical progression-free survival (local progression, dis-
tant failure), 3) disease-specific survival (DSS), 4) salvage
therapy non-adaptive interval, 5) QOL, and 6) adverse
events. OS and PFS are calculated from the 1st day of
treatment to death from any cause and or to identifica-
tion of disease progression or death, respectively. Local
progression is defined as local tumor reappearance at
the primary site. Local tumor reappearance will be con-
firmed by rectal examination and imaging studies, such
as magnetic resonance imaging (MRI) or CT or biopsy
when indicated. The primarye n d p o i n ta n dt h es e c o n d -
ary endpoints are the bPFS at 7 years and OS (or DSS)
at 10 years, respectively, following initial HT with CAB
to investigate the relationship between results and even-
tual recurrence after completion of trimodality therapy.
Planned statistical analyses
It has been shown that the 7-year bPFS rate ranges from
67.8% to 83% in patients with high-risk PCa who
undergo combination of BT and EBRT or trimodality
treatment [5,20]. Based on these two reports, the 7-year
bPFS rate of the short-term HT group is estimated to
be 75%. On the other hand, the 7-year bPFS rate of the
long-term HT group is estimated to be 87.5% (i.e.,
hazard ratio = 0.464) based on three RCTs comparing
EBRT plus long-term HT with EBRT alone [10-12].
Taken together, 153 patients for each group are needed
to detect a significant difference between treatments by
log-rank test with a significance level of 0.05 and a
power of 80%. Given the further assumption that
approximately 10% of randomized patients will not be
evaluable for various reasons, the target sample size was
set at 170 patients per group (340 total).
Statistical analyses will be performed on an intention-
to-treat basis. Survival curves will be estimated using
the Kaplan-Meier method. The log-rank test will be
used to test for differences in survival curves between
the two groups of patients. The hazard ratio will be
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longitudinal change of QOL scores (IPSS, SF-8™, EPIC)
between diagnosis and 60 months following
125I-BT will
also be compared between groups. Patients will be eval-
uated for toxicity, graded according to the National
Cancer Institute Common Toxicity Criteria version 4.0
(http://evs.nci.nih.gov/ftp1/CTCAE/About.html). For all
patients, the incident proportion of grade 3 adverse
events will be compared between groups by Fisher’s
exact test. All tests will be two-sided, and a P-value of
0.05 will be considered statistically significant. Five years
after the last patient is recruited, an interim analysis will
be performed and the results will be reported to the
Independent Data Monitoring Committee.
Patient enrollment and anticipated completion of
enrollment
Our current expectation is that the final patient will be
enrolled by September 2012, the study will be clinically
complete by 2022, and the results will be available dur-
ing the first quarter of 2023. Monthly enrollment was
going well for the goal of a total of 340 cases, actually,
cumulative enrollment reached 130 cases in September
2011.
Discussion
High-risk PCa features are associated with poor patholo-
gical outcomes after RP [3,21]. Increasing Gleason score,
high PSA level, and advanced clinical stage have all been
shown to be correlated with EPE, SV invasion, and posi-
tive surgical margins. Both Partin’st a b l e sa n dN a i t o ’s
Japanese nomograms have demonstrated the increased
incidence of the above-mentioned pathological findings
with higher risk features [22,23]. These pathological
findings have also been shown to be associated with
higher rates of biochemical failure [21,24]. Explanations
for these outcomes have focused on the presence of
microscopic dissemination of cancer cells at initial diag-
nosis. For this reason, little attention has been focused
on optimizing local control and more on developing
new systemic approaches. The patterns of failure follow-
ing standard treatment for high-risk PCa reveal a large
component of local recurrence in addition to distant
spread of disease [25,26].
In patients at greater risk for EPE, a BT boost com-
bined with additional EBRT can ensure adequate margin
of coverage of surrounding tissues even in the case of
minimal spread of disease. As there is mounting evi-
dence that dose escalation leads to a decrease in the
rate of treatment failure [27-29], this combined BT and
supplemental EBRT is now commonly used to provide a
very conformal high-dose-boost to the prostate. Indeed,
this synergistic effect of the combination strategy of two
types of RT can induce a greater biologically effective
dose (BED), the values of which are strongly correlated
with treatment outcomes in biochemical control of dis-
ease [6,30]. Stone et al. have shown that local control
improves from 78% to 98% (as determined by biopsy)
when the BED is increased from ≤ 150 Gy to > 200 Gy
[31]. Our protocol with combination of BT boost and
EBRT should deliver similar high doses, thus greatly
decreasing the likelihood that local failure will be
responsible for future PSA increase. The protocol also
allows centers to adjust their EBRT component based
on the delivered D90 so the final BED will be between
200 and 220 Gy. This RCT will be the first to test the
hypothesis of whether longer use of HT can prevent
relapse and death that results from coexistent microme-
tastases when high-risk PCa is treated with high radia-
tion doses. Zelefsky et al. have shown that even 81 Gy
of IMRT is associated with a much higher local failure
(12%) and that I-125 monotherapy is superior to 81 Gy
in both biochemical control and achieving a lower PSA
nadir [29].
The combination of HT has an independent cytotoxic
effect on prostate cancer cells, and the rationale for
combining HT with radiation is to act as a “sensitizer”
for radiation to enhance the cytotoxic effect on cancer
cells, and to eradicate micrometastatic disease beyond
the radiation volume. Several RCTs have documented a
prolongation in DSS and/or OS when HT is added to
EBRT in comparison to EBRT alone in the treatment of
men with localized high-risk and locally advanced PCa
[10-12]. Recently, Widmark et al. reported that DSS and
OS at 10 years were significantly higher with HT plus
EBRT than with HT alone [32]. However, as mentioned
above these studies were performed with insufficient
radiation dose and whether the benefit from the pro-
longed HT was from a local or distant effect, or a com-
bination of both is unknown. The majority of these
prior RCTs were performed with conventional doses of
EBRT (65-70 Gy) and it remains to be seen how the stu-
dies would turn out if higher IMRT doses were used.
However, even 81 Gy of IMRT might prove insufficient
to control the local disease in high-risk PCa.
There are several aspects of our study that are similar
to the RCTs done with HT for breast cancer. In several
trials that directly compared approximately 5 years of
tamoxifen with 1 to 2 years involving more than 18,000
women, with a mean length of follow-up of 5 person-
years, the estimated risk reductions were 15% (P <
0.001) for recurrence and 8% (P = 0.01) for breast can-
cer mortality [33]. An important feature for the breast
cancer RCTs was the success of the combined modality
therapy in treating the primary lesion, lumpectomy and
whole breast irradiation. The risk of local recurrence
after the primary treatment is less than 5%. Thus the
breast cancer RCTs were testing the hypothesis that
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cer related death.
Adequate local control has been the challenge when
treating locally advanced and high grade PCa. Often
patients are offered radical prostatectomy, especially if
they are young. However, three recent RCTs involving
adjuvant EBRT following RP demonstrated markedly
decreased local recurrence and improved survival in the
EBRT arm [34-36]. As discussed above, achieving an
adequate dose of IMRT to eradicate all local disease is
not currently possible. The need for very high local dose
was recently shown in a multicenter report in Gleason
score 8-10 PCa where patients receiving a BED of > 220
Gy (I-125 implant D90 of 130 Gy combined with 45 Gy
EBRT) had a 25% improvement in biochemical control,
decreased bone metastases and improved survival when
compared to men who received lower dose of irradiation
[6].
Relatively few data are available, mostly from single
institutions, on the morbidity of this combined modality
treatment, despite the increased use of this treatment
strategy during the 1990s [37-40]. Since the 1990s, ultra-
sound-guided transperineal interstitial permanent BT
has been a commonly used treatment strategy for
patients with PCa [17,41]. In Japan,
125I-BT was added
to the Japanese armamentarium for treatment of loca-
lized PCa in 2003 [15]. Since then, more than 10,000
patients have undergone this procedure. Although there
are many benefits of combined use of HT with EBRT,
the potential adverse events significantly caused by this
treatment should be taken into consideration [13,42].
The PROST-QA study prospectively measured patient-
reported QOL outcomes before and after PCa treatment
[14]. Sexual function was persistently poorer among
radiation patients who received HT than among those
who did not. Vitality and other outcomes related to HT
(e.g., fatigue, weight change, gynecomastia, depression,
and hot flashes) were also poorer in the HT patients. In
contrast, a meta-analysis of randomized trials suggested
that HT plus RT decreases recurrence and mortality
rates of patients with high-risk PCa, without affecting
toxicity [43].
The optimal duration of concomitant HT for high-risk
PCa when combined with dose-escalated RT is not yet
known. The period of 3 years of adjuvant HT was cho-
sen empirically; shortening of this period would reduce
costs and side effects due to longer HT and may be pos-
sible, as patients with locally advanced prostate cancer
in the late 1990s had less tumor burden and were
younger than those of the mid-1980s. The RTOG study
92-02 demonstrated that the additional 2.5 years of HT
to EBRT group showed significant improvement over
EBRT alone for all endpoints except OS in comparison
t o4m o n t h so fH Tw i t hE B R T[ 1 1 ] .T h eE O R T Cs t u d y
22961 also showed that the combination of EBRT plus
short-term HT provides inferior survival to EBRT plus
long-term HT for 3 years in the treatment of locally
advanced PCa [12].
On the other hand, the role of HT in conjunction
with BT for high-risk PCa patients is not as clearly
defined. Moreover, the ABS also provides no clear indi-
cation for adjuvant HT when combination of BT and
EBRT are performed for intermediate- to high-risk PCa,
e x c e p ti nt h ea i mo fd o w n s i z i n gt h ep r o s t a t eg l a n d
when the initial size surpasses 60 cc [7]. Although some
authors have certainly reported clinical advantages to
addition of HT to BT [20,44,45], a large retrospective
matched-pair analysis failed to show a benefit of HT in
conjunction with BT for any risk group, Gleason score,
pretreatment PSA level, or clinical stage [46]. Taken
together, the lack of evidence from randomized trials
has resulted in a variety of treatment approaches per-
formed in both clinical community and academic set-
tings, so that variations in sequence of EBRT and BT,
choice of isotope, use of HT, and the experience of
reporting institutions have all led to uncertainties in
extrapolating reported results. Furthermore, there is still
uncertainty regarding not only the adequate duration of
HT but also both the optimal timing and contents of
HT, with regard to adding HT to EBRT and/or BT in
high-risk PCa.
Accordingly, we have designed this TRIP study of tri-
modality treatment consisting of
125I-BT, EBRT, and
either short- or long- term HT for high-risk PCa. To
our knowledge, there have been no previous reports of
prospective studies documenting the efficacy and safety
of trimodality therapy for high-risk PCa patients. Initi-
ally, we assess the tumor control outcomes of patients
treated with this modality (BT and supplemental EBRT
with neoadjuvant and concurrent HT) with or without
adjuvant HT for 2 years. In this setting, the present
multi-institutional TRIP study was designed to deter-
mine the efficacy of the combination of EBRT with
125I-
BT boost in all patients treated with uniform widely
accepted guidelines for RT in addition to use of HT.
Although Lee et al. reported a significant advantage of
adding HT to BT in patients with high-risk PCa,
improvements in biochemical outcome were restricted
to those patients with “low-dose” implants [44]. In addi-
tion, the ability to adequately irradiate the periprostatic
region using extracapsular seeds may also improve bio-
chemical outcome. Taking into account the potential
learning curve for
125I-BT, participating institutions in
our study were required to have performed at least 50
previous
125I-BT procedures, thus mitigating the impact
of inexperience with this procedure while being inclu-
sive of the majority of facilities at which
125I-BT is per-
formed. In addition a dosimetry assessment committee
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Page 7 of 10will review the BT outcomes of all participants. Given
the variable nature of delivered implant dose, all centers
will be encouraged to irradiate their patients to a dose
of 200-220 Gy, in the event the implant dose is too low
or high. The uniformity of dose delivery will more clo-
sely mimic a much higher, more homogeneous dose of
EBRT. Finally, this RCT also provided additional insight
regarding the efficacy and limitations of the addition of
2 years of adjuvant HT to this trimodality therapy (dose
escalated RT plus HT before and during RT), with eva-
luation of the primary endpoint of bPFS at 7 years.
Insight should be gained as to whether extended HT
would benefit the patients who harbor micrometastases
when adequate local therapy has been delivered.
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